MCID: MRG003
MIFTS: 56

Marginal Zone B-Cell Lymphoma

Categories: Rare diseases, Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Marginal Zone B-Cell Lymphoma

MalaCards integrated aliases for Marginal Zone B-Cell Lymphoma:

Name: Marginal Zone B-Cell Lymphoma 38 12 15 73
Marginal Zone Lymphoma 12 53
Mucosa-Associated Lymphoid Tissue Lymphoma 73
Mzl 53

Classifications:



External Ids:

Disease Ontology 12 DOID:0050748

Summaries for Marginal Zone B-Cell Lymphoma

Disease Ontology : 12 A B-cell lymphoma that is characterized by initial formation in the marginal zones of lymph tissue.

MalaCards based summary : Marginal Zone B-Cell Lymphoma, also known as marginal zone lymphoma, is related to primary cutaneous marginal zone b-cell lymphoma and nodal marginal zone b-cell lymphoma. An important gene associated with Marginal Zone B-Cell Lymphoma is MALT1 (MALT1 Paracaspase), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Amoxicillin and Clarithromycin have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Marginal Zone B-Cell Lymphoma

Diseases related to Marginal Zone B-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 136)
# Related Disease Score Top Affiliating Genes
1 primary cutaneous marginal zone b-cell lymphoma 34.7 BCL10 IRF4 MALT1
2 nodal marginal zone b-cell lymphoma 34.4 BCL2 BCL6 MALT1
3 splenic marginal zone lymphoma 32.5 BCL6 BIRC3 CD5 MALT1
4 lymphoma 31.8 BCL10 BCL2 BCL6 MALT1
5 composite lymphoma 31.1 BCL6 CD5
6 peripheral t-cell lymphoma 30.2 BCL6 CD5 MME
7 lymphoma, mucosa-associated lymphoid type 30.1 BCL10 BCL2 BCL6 BIRC3 CD5 IRF4
8 b-cell lymphomas 29.3 BCL10 BCL2 BCL6 BIRC3 CD5 IRF4
9 follicular lymphoma 28.8 BCL10 BCL2 BCL6 IRF4 MME
10 mantle cell lymphoma 28.7 BCL2 BCL6 CD40LG CD5 MALT1 MME
11 diffuse large b-cell lymphoma 28.6 BCL10 BCL6 CD5 IRF4 MALT1 MME
12 leukemia, chronic lymphocytic 27.7 BCL10 BCL2 BCL6 CD40LG CD5 TLR9
13 nodal marginal zone lymphoma 11.7
14 breast lymphoma 10.7 BCL6 CD5
15 primary cutaneous diffuse large b-cell lymphoma, leg type 10.6 IRF4 MYD88
16 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.6 BCL2 BCL6
17 cryoglobulinemia, familial mixed 10.6 CD40LG CD5
18 hepatitis 10.5
19 heavy chain disease 10.5 CD40LG MYD88
20 primary effusion lymphoma 10.5 BCL6 IRF4
21 orofaciodigital syndrome viii 10.5 BCL10 BIRC3 MALT1
22 prostate lymphoma 10.5 BIRC3 CD5 MALT1
23 monoclonal paraproteinemia 10.5 CD40LG MYD88
24 ectopic thymus 10.5 BCL2 CD5
25 dendritic cell thymoma 10.5 BCL2 CD5
26 epithelial malignant thymoma 10.5 BCL2 CD5
27 immunodeficiency 17 10.5 CD40LG MALT1
28 epidural neoplasm 10.4 BCL6 CD5
29 colon lymphoma 10.4 BCL6 CD5 IRF4
30 central nervous system lymphoma 10.4 BCL6 MALT1 MYD88
31 human herpesvirus 8 10.4 BCL2 BCL6
32 histiocytosis 10.4
33 thyroiditis 10.4
34 amyloidosis 10.4
35 gallbladder lymphoma 10.4 BCL6 MME
36 heart lymphoma 10.4 BCL6 MME
37 iridocyclitis 10.4 CD40LG TNFAIP3
38 angioimmunoblastic t-cell lymphoma 10.3 BCL6 MME
39 tracheal lymphoma 10.3 CD5 MME
40 arthritis 10.3
41 plasmacytoma 10.3
42 follicular lymphoma 1 10.3 BCL10 BCL2 BCL6
43 gastric lymphoma 10.3 BCL10 BCL2 BCL6
44 primary mediastinal large b-cell lymphoma 10.3 BCL2 BCL6 IRF4
45 t-cell/histiocyte rich large b cell lymphoma 10.3 BCL6 MME
46 rheumatoid arthritis 10.3
47 hepatitis c 10.3
48 macroglobulinemia 10.3
49 plasma protein metabolism disease 10.2 CD40LG CD5 MYD88
50 gamma heavy chain disease 10.2 CD40LG MYD88

Graphical network of the top 20 diseases related to Marginal Zone B-Cell Lymphoma:



Diseases related to Marginal Zone B-Cell Lymphoma

Symptoms & Phenotypes for Marginal Zone B-Cell Lymphoma

GenomeRNAi Phenotypes related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 MALT1 MYD88 TNFAIP3 BCL10 BCL2 BIRC3
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 MALT1 MYD88 TNFAIP3 BCL10 BCL2 BIRC3

MGI Mouse Phenotypes related to Marginal Zone B-Cell Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.81 IRF4 MYD88 TLR9 BCL10 TNFAIP3 BCL2
2 hematopoietic system MP:0005397 9.7 CD5 IRF4 MALT1 MYD88 TLR9 BCL10
3 immune system MP:0005387 9.4 IRF4 MALT1 MME MYD88 TLR9 BCL10

Drugs & Therapeutics for Marginal Zone B-Cell Lymphoma

Drugs for Marginal Zone B-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 486)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 26787-78-0 33613
2
Clarithromycin Approved Phase 4,Phase 3,Phase 2,Not Applicable 81103-11-9 84029
3
Metronidazole Approved Phase 4,Phase 3,Phase 2 443-48-1 4173
4
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
5
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 135968-09-1
6
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 52-24-4 5453
7
Esomeprazole Approved, Investigational Phase 4,Phase 2 161796-78-7, 119141-88-7 4594 9579578
8
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
9 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Proton Pump Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
18 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
19 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
20 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
21 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
22 Antacids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Antimalarials Phase 4,Phase 2,Phase 1
25
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
26
Fludarabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
27
Pixantrone Approved, Investigational Phase 3 144510-96-3
28
rituximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 174722-31-7 10201696
29
Vidarabine Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 24356-66-9 32326 21704
30
Ciprofloxacin Approved, Investigational Phase 3,Not Applicable 85721-33-1 2764
31
Iron Approved Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
32
Cefepime Approved, Investigational Phase 3,Phase 1 88040-23-7 5479537
33
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
34
Ofloxacin Approved Phase 3 82419-36-1 4583
35
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 55-98-1 2478
36
Idarubicin Approved Phase 3 58957-92-9 42890
37
Melphalan Approved Phase 3,Phase 2,Phase 1,Not Applicable 148-82-3 4053 460612
38
Chlorambucil Approved Phase 3,Phase 2 305-03-3 2708
39
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
40
Doxorubicin Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 23214-92-8 31703
41
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
42
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
43
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
44
Lenalidomide Approved Phase 3,Phase 2,Phase 1 191732-72-6 216326
45
Carboplatin Approved Phase 2, Phase 3,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
46
Etoposide Approved Phase 2, Phase 3,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
47
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 128794-94-5 5281078
48
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
49
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
50
Dexlansoprazole Approved, Investigational Phase 3,Phase 2 138530-94-6, 103577-45-3 9578005

Interventional clinical trials:

(show top 50) (show all 697)
# Name Status NCT ID Phase Drugs
1 10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection Completed NCT02959255 Phase 4 Esomeprazole
2 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
3 High Dose Dual Therapy (HDDT) for Eradication of Helicobacter Pylori Infection Recruiting NCT02553083 Phase 4 Nexium 40 mg;amoxicillin 1.5 gr;doxycycline 200 mg;Nexium 20 mg;clarythromicin 500 mg;amoxicillin 1gr
4 Helicobacter – Lymphoma – Radiation Part I: Eradication, Part II: Radiation Unknown status NCT00154440 Phase 3 proton pump inhibitor;clarithromycin;amoxicillin;metronidazole
5 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
6 Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
7 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
8 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
9 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
10 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
11 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
12 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
13 Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
14 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
15 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
16 Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia Completed NCT00566332 Phase 3 Chlorambucil;Fludarabine
17 Low-Dose Radiation Therapy in Treating Patients With Follicular or Marginal Zone Non-Hodgkin's Lymphoma Completed NCT00310167 Phase 3
18 Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma Completed NCT01701232 Phase 3
19 A Phase Ⅲ Clinical Trial With Oral Recombinant Helicobacter Pylori Vaccine in Chinese Children Completed NCT02302170 Phase 3
20 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. Completed NCT00801281 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2
21 Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn Completed NCT00255190 Phase 3 Dexlansoprazole MR;Dexlansoprazole MR
22 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
23 Bendamustine Plus Rituximab Versus CHOP Plus Rituximab Completed NCT00991211 Phase 3 Bendamustine;Standard chemotherapy CHOP + Ritiximab
24 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
25 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
26 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
27 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
28 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
29 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
30 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
31 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
32 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
33 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
34 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
35 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
36 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
37 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
38 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
39 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
40 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
41 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
42 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
43 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
44 Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma Completed NCT00004112 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
45 Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00278421 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
46 Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Completed NCT00278408 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
47 Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer Completed NCT00053053 Phase 3
48 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
49 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
50 Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease Completed NCT00003414 Phase 3 busulfan;cyclophosphamide;cyclosporine

Search NIH Clinical Center for Marginal Zone B-Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Marginal Zone B-Cell Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Marginal Zone B-Cell Lymphoma

Anatomical Context for Marginal Zone B-Cell Lymphoma

MalaCards organs/tissues related to Marginal Zone B-Cell Lymphoma:

41
B Cells, Bone, Bone Marrow, T Cells, Liver, Kidney, Myeloid

Publications for Marginal Zone B-Cell Lymphoma

Articles related to Marginal Zone B-Cell Lymphoma:

(show top 50) (show all 420)
# Title Authors Year
1
Pulmonary extranodal marginal zone B-cell lymphoma of mucosa-associated lymph tissue: A case report and literature review. ( 29519992 )
2018
2
Meningeal marginal zone B-cell lymphoma: The meningioma trap. ( 29331570 )
2018
3
Isolated superior oblique muscle extranodal marginal zone B cell lymphoma: case report. ( 29755275 )
2018
4
Toll-like receptor expression and function differ between splenic marginal zone B cell lymphoma and splenic diffuse red pulp B cell lymphoma. ( 29805758 )
2018
5
A case report of unusual cavity presentation of pulmonary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. ( 29979424 )
2018
6
Full circle: Extranodal marginal zone B-cell lymphoma of the trachea. ( 28838381 )
2017
7
Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue with plasma cell differentiation: Periodic acid-schiff reaction-positive Dutcher body is a diagnostic clue to distinguish it from plasmacytoma. ( 28233949 )
2017
8
Comparative gene-expression profiling of the large cell variant of gastrointestinal marginal-zone B-cell lymphoma. ( 28729720 )
2017
9
Characteristics of primary extranodal marginal zone B-cell lymphoma in Korea: conjunctiva versus other ocular adnexa. ( 28814410 )
2017
10
Image Gallery: Metachronic occurrence of primary cutaneous marginal zone B-cell lymphoma and primary cutaneous Rosai-Dorfman disease in the same patient. ( 29313941 )
2017
11
Incidentally Discovered Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue in the Colon. ( 29348755 )
2017
12
Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). ( 28833354 )
2017
13
Change of Serum IgG4 in Patients with Ocular Adnexal Marginal Zone B Cell Lymphoma Associated with IgG4-Related Ophthalmic Disease After Treatment. ( 28514197 )
2017
14
A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma. ( 28695630 )
2017
15
Extranodal marginal zone B cell lymphoma: An unexpected complication in children with SjAPgren's syndrome. ( 28284773 )
2017
16
Treatment outcomes in patients with extranodal marginal zone B-cell lymphoma of the lung. ( 28457544 )
2017
17
Frequent immunoglobulin G4 expression in a common variant of primary cutaneous marginal zone B-cell lymphoma. ( 28980311 )
2017
18
Bilateral orbital marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue in a patient with hepatitis B virus infection. ( 29260074 )
2017
19
Primary hepatic extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type: A case report and literature review. ( 28353562 )
2017
20
Usefulness of Flow Cytometry in Diagnosis of IgG4-Related Ophthalmic Disease and Extranodal Marginal Zone B-Cell Lymphoma of the Ocular Adnexa. ( 28870925 )
2017
21
Marginal zone B-cell lymphoma mimicking extramedullary plasmacytoma and the clinical outcome after treatment. ( 28507591 )
2017
22
Low Dose Radiation Therapy for Primary Conjunctival Marginal Zone B-cell Lymphoma. ( 28618774 )
2017
23
Extranodal Marginal Zone B-cell Lymphoma of the Ocular Adnexa. ( 27218791 )
2016
24
Intracranial marginal zone B-cell lymphoma mimicking meningioma: case report. ( 27155383 )
2016
25
Primary Cutaneous Marginal Zone B-Cell Lymphoma Presenting as a Small Mass on Temple Area. ( 27152562 )
2016
26
The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma. ( 27443419 )
2016
27
Gender Aspects in Extranodal Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue: Does Sex Matter? ( 27548082 )
2016
28
Clinicopathological features of histological transformation from extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue to diffuse large B-cell lymphoma: an analysis of 467 patients. ( 27460179 )
2016
29
Misdiagnosis of primary hepatic marginal zone B cell lymphoma of mucosa-associated lymphoid tissue type, a case report. ( 26956381 )
2016
30
Lacrimal gland extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue-type associated with massive amyloid deposition. ( 27010357 )
2016
31
Primary Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue of the Lacrimal Sac Found with Epiphora: A Case Report. ( 27790131 )
2016
32
Extranodal pulmonary marginal zone B-cell lymphoma. ( 27330951 )
2016
33
Paediatric primary cutaneous marginal zone B-cell lymphoma: Does it differ from the adult counterpart? ( 27501236 )
2016
34
Epidermotropic skin involvement of splenic marginal zone B-cell lymphoma: a diagnostic challenge. ( 28008643 )
2016
35
Primary thymic extranodal marginal zone B cell lymphoma as an incidental finding in a Caucasian woman. ( 26338245 )
2015
36
Primary extranodal marginal zone B-cell lymphoma with diffuse uveal involvement and focal infiltration of the trabecular meshwork: a case report and review of literature. ( 25947067 )
2015
37
77-year-old woman with a dural-based mass. Marginal zone B-cell lymphoma (MZBCL). ( 25521182 )
2015
38
A case of marginal zone B cell lymphoma mimicking IgG4-related dacryoadenitis and sialoadenitis. ( 25889621 )
2015
39
A 44-year old male with right-sided facial numbness. Dura-associated extranodal marginal zone B cell lymphoma (MALT lymphoma). ( 25521183 )
2015
40
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Tissue Type involving the Dura. ( 26194368 )
2015
41
A case of contiguous primary hepatic marginal zone B-cell lymphoma and hemangioma ultimately diagnosed using contrast-enhanced ultrasonography. ( 25848352 )
2015
42
Marginal zone B-cell lymphoma of the pulmonary mucosa-associated lymphoid tissue: A case report. ( 26622741 )
2015
43
Clinicopathological Analysis of Ocular Adnexal Extranodal Marginal Zone B-Cell Lymphoma with IgG4-Positive Cells. ( 26111022 )
2015
44
MYD88 (L265P) Somatic Mutation in Marginal Zone B-cell Lymphoma. ( 25723115 )
2015
45
Primary Cutaneous Marginal Zone B Cell Lymphoma of the Eyelid Skin: Diagnostic Clues and Distinction from Other Ocular Adnexal Disease. ( 26545575 )
2015
46
Conjunctival extranodal marginal zone B-cell lymphoma with crystal-storing histiocytosis. ( 25988528 )
2015
47
Bilateral Bronchiectasis as a Presentation Form of Pulmonary Marginal Zone B-Cell Lymphoma of Bronchus Associated Lymphoid Tissue. ( 26839723 )
2015
48
Radiation Therapy Administration and Survival in Stage I/II Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue. ( 24411627 )
2014
49
IgG4-related dacryoadenitis evolving into an extra-nodal, marginal zone B-cell lymphoma (EMZL): a tale of two lacrimal glands. ( 24977741 )
2014
50
Crystal storing histiocytosis associated with marginal zone B-cell lymphoma: A rare initial clinical presentation diagnosed by fine-needle aspiration. ( 25071859 )
2014

Variations for Marginal Zone B-Cell Lymphoma

Expression for Marginal Zone B-Cell Lymphoma

Search GEO for disease gene expression data for Marginal Zone B-Cell Lymphoma.

Pathways for Marginal Zone B-Cell Lymphoma

Pathways related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.69 BCL10 BCL2 BCL6 BIRC3 C1S CD40LG
2
Show member pathways
13.2 BCL2 BCL6 BIRC3 CD40LG IRF4 MYD88
3
Show member pathways
12.84 BCL2 BIRC3 MYD88 TLR9 TNFAIP3
4
Show member pathways
12.53 BCL10 CD40LG MALT1 MYD88 TLR9 TNFAIP3
5
Show member pathways
12.29 BCL10 CD40LG IRF4 MALT1
6
Show member pathways
12.22 BCL10 BCL6 IRF4 MALT1
7
Show member pathways
12.16 BCL2 BIRC3 CD40LG MYD88 TLR9 TNFAIP3
8
Show member pathways
12.1 BCL2 BIRC3 CD40LG MYD88
9 12.07 BCL10 BCL6 CD40LG IRF4 MALT1 MYD88
10 12.05 BCL10 BCL2 MALT1 MYD88 TLR9
11
Show member pathways
12.03 BCL2 BIRC3 TNFAIP3
12
Show member pathways
12.03 BCL10 MALT1 MYD88 TLR9
13 12 BCL10 BCL2 BIRC3 CD40LG MALT1 TNFAIP3
14
Show member pathways
11.84 BCL2 BIRC3 TNFAIP3
15 11.83 BCL2 BCL6 IRF4
16 11.62 IRF4 MME TLR9
17
Show member pathways
11.61 BCL2 BIRC3 CD40LG
18 11.59 MALT1 MYD88 TNFAIP3
19 11.51 BCL6 CD40LG IRF4
20 11.39 BCL6 CD40LG CD5 MME
21 11.38 CD40LG MYD88 TLR9
22 11.15 BCL10 BCL2 BIRC3 CD40LG MALT1 MYD88
23 11.13 BIRC3 CD40LG TNFAIP3
24 10.99 BCL10 MALT1 TNFAIP3

GO Terms for Marginal Zone B-Cell Lymphoma

Cellular components related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CBM complex GO:0032449 8.62 BCL10 MALT1

Biological processes related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.99 BCL10 BCL2 BIRC3 MYD88 TNFAIP3
2 immune system process GO:0002376 9.96 BCL10 BCL6 C1S MYD88 TLR9
3 innate immune response GO:0045087 9.95 BCL10 C1S MALT1 MYD88 TLR9
4 cytokine-mediated signaling pathway GO:0019221 9.88 BCL2 BCL6 IRF4 MYD88
5 inflammatory response GO:0006954 9.83 BCL6 CD40LG MYD88 TLR9 TNFAIP3
6 negative regulation of apoptotic process GO:0043066 9.8 BCL2 BCL6 BIRC3 CD40LG MALT1 MYD88
7 regulation of apoptotic process GO:0042981 9.77 BCL10 BCL2 BCL6 BIRC3 MALT1
8 protein complex oligomerization GO:0051259 9.74 BCL10 MALT1 TNFAIP3
9 B cell differentiation GO:0030183 9.71 BCL2 BCL6 CD40LG
10 positive regulation of protein ubiquitination GO:0031398 9.69 BCL10 BIRC3 MALT1
11 negative regulation of interleukin-6 production GO:0032715 9.63 TLR9 TNFAIP3
12 toll-like receptor signaling pathway GO:0002224 9.63 BCL10 MYD88 TLR9
13 positive regulation of interleukin-12 production GO:0032735 9.62 CD40LG TLR9
14 positive regulation of T cell activation GO:0050870 9.62 BCL10 MALT1
15 positive regulation of interleukin-10 production GO:0032733 9.61 CD40LG TLR9
16 toll-like receptor 9 signaling pathway GO:0034162 9.61 MYD88 TLR9
17 negative regulation of toll-like receptor signaling pathway GO:0034122 9.6 IRF4 TLR9
18 immunoglobulin mediated immune response GO:0016064 9.58 BCL10 MYD88
19 positive regulation of B cell proliferation GO:0030890 9.58 BCL2 BCL6 TLR9
20 regulation of inflammatory response GO:0050727 9.56 BCL6 BIRC3 MYD88 TNFAIP3
21 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.55 BCL10 CD40LG MALT1 MYD88 TLR9
22 response to fungus GO:0009620 9.52 BCL10 MALT1
23 regulation of T cell receptor signaling pathway GO:0050856 9.49 BCL10 MALT1
24 regulation of germinal center formation GO:0002634 9.48 BCL6 TNFAIP3
25 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.43 BCL10 BIRC3 MALT1 MYD88 SLC35B2 TLR9
26 response to molecule of bacterial origin GO:0002237 8.92 BCL10 MALT1 TLR9 TNFAIP3

Molecular functions related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.7 BCL10 BCL2 BCL6 C1S MALT1 MYD88
2 interleukin-1 receptor binding GO:0005149 9.32 MYD88 TLR9
3 kinase activator activity GO:0019209 9.26 BCL10 MALT1
4 protease binding GO:0002020 9.26 BCL10 BCL2 MALT1 TNFAIP3
5 protein self-association GO:0043621 8.92 BCL10 MALT1 MYD88 TNFAIP3
6 protein binding GO:0005515 10.18 BCL10 BCL2 BCL6 BIRC3 C1S CD40LG

Sources for Marginal Zone B-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....